FDA approves Abbott's AndroGel for hypogonadism treatment in men
Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.
Linear Mode
